Distinct distribution of corticotropin releasing factor receptors in human breast cancer

Neuropeptides
A KapraraE Chatzaki

Abstract

The hypothalamic neuropeptide corticotropin releasing factor (CRF) has been found in several types of human cancer, where its biological role is not clarified. In experimental models of breast cancer CRF has been shown to exert anti-proliferative and other actions. Aim of the present study was to describe the expression of the two types of CRF receptors CRF(1) and CRF(2) in human breast tumors. Receptor expression was studied in breast biopsies from patients diagnosed for primary breast adenocarcinoma, obtained from the tumor and the adjacent benign tissue. Gene expression levels were evaluated by real-time PCR following reverse transcription of total RNA extracts. CRF(1) transcripts were found in 23.1% of benign and in 23.1% of malignant biopsies. CRF(2(a)) was found in 22.2% of benign and 36.0% of malignant biopsies. Transcript levels of both receptors did not differ significantly between cancer and benign biopsies from the same tumor. No correlation was found between CRF receptor expression and patient histo/clinicopathological characteristics. Histological mapping using immunohistochemistry revealed positive CRF(1) immunostaining in the cancerous implants and breast ducts, whereas CRF(2) immunoreactivity was localized mainl...Continue Reading

References

Nov 13, 1987·Biochemical and Biophysical Research Communications·M GrinoA N Margioris
Oct 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·R ChenW W Vale
Jan 31, 1995·Proceedings of the National Academy of Sciences of the United States of America·T W LovenbergT Oltersdorf
Nov 26, 1999·The Journal of Investigative Dermatology·J L ArbiserJ A Majzoub
Jan 12, 2000·Molecular and Cellular Endocrinology·B K BrarD S Latchman
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Jan 10, 2003·The Journal of Clinical Endocrinology and Metabolism·E ChatzakiA Gravanis
Mar 29, 2003·European Journal of Nuclear Medicine and Molecular Imaging·Philipp Mayer-KuckukDebabrata Banerjee
Apr 15, 2003·Nihon Shinkei Seishin Yakurigaku Zasshi = Japanese Journal of Psychopharmacology·Hideaki NagashimaSachiko Fujii
Jul 5, 2003·The Journal of Clinical Endocrinology and Metabolism·Jean Claude ReubiJean Rivier
Jan 28, 2004·Annual Review of Pharmacology and Toxicology·Tracy L Bale, Wylie W Vale
Jul 2, 2004·Journal of Neurochemistry·Ekaterini ChatzakiDimitri E Grigoriadis
Mar 15, 2006·Neuroendocrinology·Ekaterini ChatzakiKonstantinos Simopoulos
Apr 22, 2006·American Journal of Obstetrics and Gynecology·Alberto ImperatoreFelice Petraglia
Jul 14, 2006·The Journal of Endocrinology·Pasquale FlorioFelice Petraglia
Dec 20, 2008·Neuroendocrinology·Constantinos SimopoulosEkaterini Chatzaki
May 13, 2009·Molecular and Cellular Endocrinology·Fiorella MiceliGabriella Ferrandina
Jun 6, 2009·Molecular Cancer·Ariadne AndroulidakiChristos Tsatsanis
Feb 10, 2010·Cellular and Molecular Life Sciences : CMLS·Athina KapraraEkaterini Chatzaki

❮ Previous
Next ❯

Citations

Jul 4, 2013·Science Signaling·Suchita LalDimitris K Grammatopoulos
Sep 21, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Linda E B StuhrRolf K Reed
Sep 26, 2014·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Naoko SatoKiyoshi Ito
Feb 14, 2013·Journal of the Royal Army Medical Corps·M MalliarouE Velonakis
Aug 14, 2013·Endocrine Reviews·Andrzej T SlominskiJean Rivier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis